148 related articles for article (PubMed ID: 33984552)
21. Chemotherapy-induced peripheral neuropathy increases nontraumatic fracture risk in breast cancer survivors.
McNeish BL; Richardson JK; Bell SG; Whitney DG
JBMR Plus; 2021 Aug; 5(8):e10519. PubMed ID: 34368609
[TBL] [Abstract][Full Text] [Related]
22. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
23. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
24. The cardiovascular disease burden of non-traumatic fractures for adults with and without cerebral palsy.
Whitney DG; Bell S; Etter JP; Prisby RD
Bone; 2020 Jul; 136():115376. PubMed ID: 32335375
[TBL] [Abstract][Full Text] [Related]
25. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.
Khatod M; Inacio MC; Dell RM; Bini SA; Paxton EW; Namba RS
Clin Orthop Relat Res; 2015 Nov; 473(11):3412-20. PubMed ID: 25896134
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries.
Rubin KH; Möller S; Choudhury A; Zorina O; Kalsekar S; Eriksen EF; Andersen M; Abrahamsen B
Bone; 2020 May; 134():115296. PubMed ID: 32097760
[TBL] [Abstract][Full Text] [Related]
28. Nitrogen-Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture.
Sing CW; Kiel DP; Hubbard RB; Lau WC; Li GH; Kung AW; Wong IC; Cheung CL
J Bone Miner Res; 2020 Sep; 35(9):1676-1684. PubMed ID: 32488902
[TBL] [Abstract][Full Text] [Related]
29. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density.
Rodríguez AJ; Ernst MT; Nybo M; Prieto-Alhambra D; Ebeling PR; Hermann AP; Abrahamsen B
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32717068
[TBL] [Abstract][Full Text] [Related]
30. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of bisphosphonate therapy in a community setting.
Feldstein AC; Weycker D; Nichols GA; Oster G; Rosales G; Boardman DL; Perrin N
Bone; 2009 Jan; 44(1):153-9. PubMed ID: 18926939
[TBL] [Abstract][Full Text] [Related]
32. The mortality burden of non-trauma fracture for adults with cerebral palsy.
Whitney DG; Bell S; Hurvitz EA; Peterson MD; Caird MS; Jepsen KJ
Bone Rep; 2020 Dec; 13():100725. PubMed ID: 33088868
[TBL] [Abstract][Full Text] [Related]
33. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
35. Time to benefit and the long-term persistence of new users of oral bisphosphonates.
Friesen KJ; Bugden S; Falk J
J Bone Miner Metab; 2020 May; 38(3):371-377. PubMed ID: 31894490
[TBL] [Abstract][Full Text] [Related]
36. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
37. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
38. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
[TBL] [Abstract][Full Text] [Related]
39. Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse R; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
J Bone Miner Res; 2019 Nov; 34(11):2001-2011. PubMed ID: 31402509
[TBL] [Abstract][Full Text] [Related]
40. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
